Endometriosis
Endometrial-like tissue growing outside the uterus — pelvic pain, dysmenorrhea, infertility, fatigue. Affects ~10% of women of reproductive age; average diagnostic delay 7–10 years.
What changes during this transition
Endometriosis is angiogenesis-dependent at the lesion level — this is the load-bearing safety variable when considering peptides, because many growth-supporting peptides have VEGF-upregulation mechanisms that could feed lesion vascularization (BPC-157 is the explicit example — community use significantly outruns the evidence, and the angiogenesis mechanism aligns with the wrong direction; substrate-only for that reason). First-line care: NSAIDs, hormonal therapy (combined OCPs, progestin-only, GnRH antagonists like elagolix/relugolix with E2/NETA add-back), and surgical excision. Peptides relevant for adjacent symptoms: kisspeptin is the ONLY library peptide with a coherent (still hypothetical) endometriosis-specific therapeutic rationale — KISS1R-mediated inhibition of ectopic endometrial cell invasion + angiogenesis in vitro. B12-methylcobalamin addresses the neuropathic-pain component (endometriosis pain has a documented neuropathic component; methylcobalamin has Tier 2 evidence for peripheral neuropathy generally). Larazotide addresses the leaky-gut hypothesis (preclinical only — gut barrier disruption is an active research direction in endometriosis pathophysiology).
Important caveat
Endometriosis deserves gynecology specialist care — peptides don't replace excision surgery, hormonal therapy, or multimodal pain management. CRITICAL: oxytocin is CONTRAINDICATED for active dysmenorrhea — it drives uterine contractility, the wrong direction for endometriosis pain. BPC-157's VEGF/angiogenesis mechanism is mechanism-aligned with feeding lesion vascularization — substrate-only, not surfaced for discovery. Endometriosis cohorts have a slight ovarian cancer association — any growth-promoting peptide layered on top deserves explicit OB-GYN surveillance.
Peptides editorially relevant to endometriosis
3 peptides from the library — each evidence-tiered honestly.
- KisspeptinTier 2
KISS1R agonist (hypothalamic neuropeptide)
Sits at the very top of the reproductive axis — triggers the cascade that produces sex hormones. Strong clinical-research evidence for hypogonadism and IVF use; off-label 'natural T' community use in healthy men runs ahead of the data.
- B12 (Methylcobalamin)Tier 1
Vitamin (methylcobalamin)
Vitamin B12 in the methyl form. Solid evidence for treating documented deficiency and pernicious anemia. The wellness-clinic 'energy injection' market for non-deficient adults has no clinical-trial support.
- LarazotideTier 2
Tight-junction modulator (gut)
Furthest-developed clinical-stage peptide for celiac disease. The pivotal Phase 3 trials missed their primary endpoints; community marketing for general 'leaky gut' goes far past the evidence.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.